POSITIVE EFFECTS OF RENAL DENERVATION ON MARKER OF CARDIOVASCULAR INFLAMMATION AND LEFT VENTRICULAR MASS. 24-MONTH FOLLOW-UP

Abstract

Objective: The C-reactive protein (hsCRP) as biomarker of vascular inflammation and remodeling is proven involved in development of left ventricular hypertrophy and determined as predictive factor of cardiovascular complications. Our objective was to study the influence of renal denervation (RDN) on left ventricular mass (LVM) and hsCRP at 24 month after the treatment and their relationship. Design and method: 20 patients with resistant hypertension aged 59.5 ± 6.1 years and 24-h blood pressure (BP) 154.8 ± 13.4/83.8 ± 13.8 mm Hg, giving inform consent, were enrolled in the study. RDN was done to all patients. Initially and at 24 months after treatment patients were measured 24-h BP, high-sensitive hsCRP by enzyme-linked immunosorbent assay (ELISA) and LVM by the cardiac magnetic resonance (CMR). Results: Based on changes of LVM at 24 month after RDN all patients retrospectively were divided into 2 groups: the 1st with changes in LVM < 0 g (n = 7) and the 2nd group with changes > 0 g (n = 13) Groups were comparable in baseline 24-h BP (158.3 ± 19.6/88.3 ± 16.2 vs 152.8 ± 8.9/81.4 ± 12.3 mm Hg, p > 0.05), LVM (214.1 ± 61.7 vs 250.3 ± 68.4 g, p = 0.26) and hsCRP (4.6 ± 3.3 vs 3.3 ± 2.8 mg/l, p = 0.41). Despite of comparable changes of SBP at 24 month after RDN (-11/-4.0 vs -15.5/-7.5 mm Hg, p = 0.19 for SBP, p = 0.87 for DBP) hsCRP decreased significantly by 33.3% (p = 0.046) in the 2nd group without significant changes in value of hsCRP in the 1st group (by 19.6%, p = 0.35). There was no correlation between changes of LVM and hsCRP at 24 month after RDN in both groups. Conclusions: The regression of hsCRP was detected in patients with decreased LVM as one of possible ways of realization cardioprotective efficacy of RDN.